Home / First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial unknow ★ 5.0 · 21 reads Sign in to save this Request CodeZLIB.IO18490953 Published2022 Pages1 LanguageUnknown